Trial Profile
A Randomized, Placebo-controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment With CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2021
Price :
$35
*
At a glance
- Drugs Brincidofovir (Primary)
- Indications Adenovirus infections
- Focus Proof of concept; Therapeutic Use
- Acronyms Adv-Halt
- Sponsors Chimerix
- 09 Sep 2014 Results presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy.
- 08 Sep 2014 Results published in the Media Release.
- 04 Nov 2013 Results presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy.